Trial Profile

Phase 1 study of Apraglutide in healthy Japanese adult men and women

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 28 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apraglutide (Primary)
Indications Graft-versus-host disease; Short bowel syndrome
Focus Adverse reactions; Pharmacokinetics; Registrational

Most Recent Events

12 Dec 2023 According to an Ironwood Pharmaceuticals media release, the VectivBio has been acquired and merged into Ironwood Pharmaceuticals.
20 Mar 2023 New trial record
13 Mar 2023 According to a VectivBio media release, this study is conducted by Asahi Kasei Pharma, is expected to be the only Japan-specific clinical study necessary to file a marketing authorization application in Japan.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com